Ahmanson/UCLA Adult Congenital Heart Disease Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
World J Pediatr Congenit Heart Surg. 2020 Jul;11(4):432-437. doi: 10.1177/2150135120918777.
For patients with combined tricuspid and pulmonary valve disease, operative intervention carries high mortality risk. Published reports of combined transcatheter tricuspid and pulmonary valve replacement have been limited to single cases.
A retrospective chart review was performed including all patients undergoing combined transcatheter tricuspid and pulmonary valve replacement at the Ahmanson/UCLA Adult Congenital Heart Disease Center.
Combined transcatheter tricuspid and pulmonary valve replacement was undertaken in five adult patients (median age: 46 years; range: 24-64 years). Three had congenital heart disease and two had carcinoid syndrome. Four patients had previous surgical tricuspid valve replacement and one had a surgical incomplete annuloplasty ring. Four patients had previous surgical pulmonary valve replacement and one had a right ventricle-to-pulmonary artery homograft conduit. Two patients underwent Medtronic Melody valve implantation in both tricuspid and pulmonary positions and three underwent Edwards Sapien S3 implantation in both tricuspid and pulmonary positions. Valve implantation was successful in all. Follow-up ranged from 0.9 to 3.0 years. One patient underwent redo transcatheter tricuspid valve replacement 12 months after the first transcatheter intervention for progressive regurgitation of a Melody valve. This patient died 2.5 years after combined valve placement of complications from refractory heart failure. The remaining patients were alive and free of valve reintervention at follow-up.
Combined transcatheter tricuspid and pulmonary valve replacement can be performed successfully, with an acceptable complication rate. This strategy is a feasible option for appropriately selected patients.
对于同时患有三尖瓣和肺动脉瓣疾病的患者,手术干预的死亡率很高。已发表的关于经导管同期三尖瓣和肺动脉瓣置换的报告仅限于单个病例。
回顾性图表分析纳入了在阿罕默森/加州大学洛杉矶分校成人先天性心脏病中心接受同期经导管三尖瓣和肺动脉瓣置换的所有患者。
5 名成年患者(中位年龄:46 岁;范围:24-64 岁)接受了同期经导管三尖瓣和肺动脉瓣置换。其中 3 例患有先天性心脏病,2 例患有类癌综合征。4 例患者曾行外科三尖瓣置换术,1 例患者曾行外科不完全瓣环成形术。4 例患者曾行外科肺动脉瓣置换术,1 例患者曾行右心室至肺动脉同种带瓣管道移植术。2 例患者在三尖瓣和肺动脉瓣位置植入了美敦力 Melody 瓣膜,3 例患者在三尖瓣和肺动脉瓣位置植入了爱德华兹 Sapien S3 瓣膜。所有患者的瓣膜植入均成功。随访时间为 0.9 至 3.0 年。1 例患者在首次经导管干预后 12 个月因 Melody 瓣膜进行性反流而行再次经导管三尖瓣置换术,该患者在同期瓣膜置入后 2.5 年死于难治性心力衰竭并发症。其余患者均存活且在随访中无瓣膜再干预。
同期经导管三尖瓣和肺动脉瓣置换术可成功实施,并发症发生率可接受。对于选择合适的患者,该策略是一种可行的选择。